CoChat

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first‐line oxaliplatin‐based treatment

Open access
Kjersem, J.B., Ikdahl, T., Lingjaerde, O.C., Guren, T., Tveit, K.M., Kure, E.H. · 2014 · Molecular Oncology
Cited by 145

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The conventional first‐line chemotherapy for metastatic colorectal cancer (mCRC) consists of fluorouracil (5‐FU) in combination with either oxaliplatin or irinotecan. We have explored microRNAs (miRNAs) in plasma as potential predictive markers to oxaliplatin‐based chemotherapy. The expression of 742 miRNAs was examined in plasma samples from 24 mCRC patients (12 responders and 12 non‐responders) before onset and after four cycles of 5‐FU/oxaliplatin. The top differentially expressed miRNAs between responders and non‐responders were selected for further analysis in a validation cohort of 150 patients. In the validation cohort, there was a significant overrepresentation of miRNAs with higher mean expression in the non‐responder group than in the responder group before treatment (p < 0.002). Moreover, we found three miRNAs (miR‐106a, miR‐484, and miR‐130b) to be significantly differentially expressed before treatment (p = 0.008, 0.008, and 0.008, respectively). All three miRNAs were upregulated in non‐responders. High expression of miR‐27b, miR‐148a, and miR‐326 were associated with decreased progression‐free survival (Hazard ratios (HR) of 1.4 (95% CI 1.1–1.8, p = 0.004), 1.3 (95% CI 1.1–1.6, p = 0.007), and 1.4 (95% CI 1.1–1.8, p = 0.008), respectively). miR‐326 was also associated with decreased overall survival (HR 1.5 (95% CI 1.1–2.0, p = 0.003)). There were no significantly differentially expressed miRNAs in association with clinical outcome after four cycles of chemotherapy. The present study demonstrates that plasma miRNAs analyzed before treatment may serve as non‐invasive markers predicting outcome in mCRC patients treated with 5‐FU and oxaliplatin‐based chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2013.09.001

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 145

Metadata

Authors
Kjersem, J. B., Ikdahl, T., Lingjaerde, O. C., Guren, T., Tveit, K. M., & Kure, E. H.
Venue
Molecular Oncology
Publisher
Wiley
Published
2013-09-21
Volume
8
Issue
1
Pages
59-67
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2053631616
Cited by
145
References
9
FWCI
5.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.